Systemic hypertension and proteinuria in childhood chronic renal parenchymal disease: Role of antihypertensive drug management

Pediatric Drugs

Volumn 9, Issue 6, 2007, Pages 413-418

  Simonetti, Giacomo D ^a   Santoro, Laura ^b,c   Ferrarini, Alessandra ^b,c   Crosazzo Franscini, Laura ^b,c   Fossali, Emilio ^d   Bianchetti, Mario G ^b,c,d  

^a UNIVERSITY OF BERN   (Switzerland)

^b OSPEDALE SAN GIOVANNI   (Switzerland)

^c Ospedale Beata Vergine   (Switzerland)

^d FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

ACE inhibitors, therapeutic use; Adrenergic receptor antagonists, therapeutic use; Amiloride, therapeutic use; Amlodipine, therapeutic use; Angiotensin II 2 receptor antagonists, therapeutic use; Atenolol, therapeutic use; Benazepril, therapeutic use

Indexed keywords

AMILORIDE; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CANDESARTAN; CHLORTALIDONE; DIHYDROPYRIDINE DERIVATIVE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FOSINOPRIL; HYDROCHLOROTHIAZIDE; IRBESARTAN; LISINOPRIL; LOSARTAN; METOPROLOL; NIFEDIPINE; QUINAPRIL; RAMIPRIL; SPIRONOLACTONE; TRIAMTERENE; VERAPAMIL;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CHILDHOOD DISEASE; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG POTENTIATION; EVALUATION; GLOMERULUS CAPILLARY; HUMAN; HYPERTENSION; KIDNEY DISEASE; KIDNEY PARENCHYMA; MONOTHERAPY; OUTCOME ASSESSMENT; PATIENT SATISFACTION; PRIORITY JOURNAL; PROTEINURIA; REVIEW; TREATMENT RESPONSE;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; CHILD; CHRONIC DISEASE; DIURETICS; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; KIDNEY DISEASES; PROTEINURIA;

EID: 36749080967     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/00148581-200709060-00008     Document Type: Review

References (41)

1. Hales CN. Suicide of the nephron. Lancet 2001; 357: 136-7
2. Remuzzi G, Ruggenenti P, Perico N. Chronic renal diseases: renoprotective benefits of renin-angiotensin system inhibition. Ann Intern Med 2002; 136: 604-15
3. Soares CM, Oliveira EA, Diniz JS, et al. Predictive factors of progression of chronic renal insufficiency: a multivariate analysis. Pediatr Nephrol 2003; 18: 371-7
4. Parekh RS, Carroll CE, Wolfe RA, et al. Cardiovascular mortality in children and young adults with end-stage kidney disease. J Pediatr 2002; 141: 191-7
5. Chavers BM, Li S, Collins AJ, et al. Cardiovascular disease in pediatric chronic dialysis patients. Kidney Int 2002; 62: 648-53
6. Groothoff JW. Long-term outcomes of children with end-stage renal disease. Pediatr Nephrol 2005; 20: 849-53
7. Lopes AA. Hypertension in black people: pathophysiology and therapeutic aspects. J Hum Hypertens 2002; 16 (1 Suppl.): S11-2
8. van der Vorst MM, Kist JE, van der Heijden AJ, et al. Diuretics in pediatrics: current knowledge and future prospects. Paediatr Drugs 2006; 8: 245-64
9. Dworkin LD, Shemin DG. Antihypertensive therapy and progression of chronic renal disease. Curr Hypertens Rep 1999; 1: 417-22
10. Textor SC, Canzanello VJ, Epstein M, et al. What is the optimal strategy to intensify blood pressure control and prevent progression of renal failure? Curr Hypertens Rep 2001; 3: 422-8
11. Weir MR. Progressive renal and cardiovascular disease: optimal treatment strategies. Kidney Int 2002; 62: 1482-92
12. Wingen AM, Fabian-Bach C, Schaefer F, et al. Randomised multicentre study of a low-protein diet on the progression of chronic renal failure in children. European Study Group of Nutritional Treatment of Chronic Renal Failure in Childhood. Lancet 1997; 349: 1117-23
13. Wenzel U. Aldosterone antagonists: silver bullet or just sodium excretion and potassium retention? Kidney Int 2007; 71: 374-6
14. Kloke HJ, Branten AJ, Huysmans FT, et al. Antihypertensive treatment of patients with proteinuric renal diseases: risks or benefits of calcium channel blockers? Kidney Int 1998; 53: 1559-73
15. Hayashi K, Ozawa Y, Fujiwara K, et al. Role of actions of calcium antagonists on efferent arterioles with special references to glomerular hypertension. Am J Nephrol 2003; 23: 229-44
16. Tobe S. Update on calcium antagonists and the kidney. Curr Opin Nephrol Hypertens 2003; 12: 309-15
17. Sahney S. A review of calcium channel antagonists in the treatment of pediatric hypertension. Paediatr Drugs 2006; 8: 357-73
18. National Kidney Foundation. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004; 1 Suppl. 43: 1-290
19. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 2004; 114: 555-76
20. Somu S, Sundaram B, Kamalanathan AN. Early detection of hypertension in general practice. Arch Dis Child 2003; 88: 302
21. Bianchetti MG, Ardissino G, Fossali E, et al. Hypertension in children and adolescents. J Hypertens 2004; 22: 2227
22. Wühl E, Mehls O, Schaefer F, et al. Antihypertensive and antiproteinuric efficacy of ramipril in children with chronic renal failure. Kidney Int 2004; 66: 768-76
23. Palmer BF. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: what to do if the serum creatinine and/or serum potassium concentration rises. Nephrol Dial Transplant 2003; 18: 1973-5
24. Perazella MA. Drug-induced hyperkalemia: old culprits and new offenders. Am J Med 2000; 109: 307-14
25. Woroniecki RP, Flynn JT. How are hypertensive children evaluated and managed? A survey of North American pediatric nephrologists. Pediatr Nephrol 2005; 20: 791-7
26. Bianchetti MG, Ammenti A, Avolio L, et al. Prescription of drugs blocking the renin-angiotensin system in Italian children. Pediatr Nephrol 2007; 22: 144-8
27. Ardissino G, Daccò V, Testa S, et al. Epidemiology of chronic renal failure in children: data from the ItalKid project. Pediatrics 2003; 111 (2 Pt 1): 382-7
28. Hilgers KF, Dötsch J, Rascher W, et al. Treatment strategies in patients with chronic renal disease: ACE inhibitors, angiotensin receptor antagonists, or both? Pediatr Nephrol 2004; 19: 956-61
29. Sieber US, von Vigier RO, Sforzini C, et al. How good is blood pressure control among treated hypertensive children and adolescents? J Hypertens 2003; 21: 633-7
30. Nevins TE. "Why do they do that?" The compliance conundrum. Pediatr Nephrol 2005; 20: 845-8
31. Bloom BS. Daily regimen and compliance with treatment. BMJ 2001; 323: 647
32. Flack JM, Yunis C, Preisser J, et al. The rapidity of drug dose escalation influences blood pressure response and adverse effects burden in patients with hypertension: the Quinapril Titration Interval Management Evaluation (ATIME) Study. ATIME Research Group. Arch Intern Med 2000; 160: 1842-7
33. von Vigier RO, Bianchetti MG. Arterielle hypertonie im kindes- und adoleszentenalter. Ther Umsch 1999; 56: 12-8
34. Simonetti GD, Fossali E, Ramelli GP, et al. Prise en charge pharmacologique de l'hypertension artérielle chronique chez l'enfant: KISS, please. Rev Med Suisse 2005; 1: 1307-10
35. Ardissino G, Edefonti A, Bianchetti MG, et al. Criteri diagnostici e terapeutici dell'ipertensione arteriosa in età pediatrica. G Ital Nefrol 2006; 23: 149-62
36. Bianchetti MG, Ardissino G, Fossali E, et al. Tips for the use of antihypertensive drugs: DELTAREPROSI. J Pediatr 2004; 145: 288-90
37. Phillips LS, Branch WT, Cook CB, et al. Clinical inertia. Ann Intern Med 2001; 135: 825-34
38. Kaplan NM. Resistant hypertension. J Hypertens 2005; 23: 1441-4
39. Lurbe E, Sorof JM, Daniels SR. Clinical and research aspects of ambulatory blood pressure monitoring in children. J Pediatr 2004; 144: 7-16
40. Calhoun DA. Use of aldosterone antagonists in resistant hypertension. Prog Cardiovasc Dis 2006; 48: 387-96
41. Sica DA. Minoxidil: an underused vasodilator for resistant or severe hypertension. J Clin Hypertens (Greenwich) 2004; 6: 283-7